525 results on '"Widmark, Anders"'
Search Results
2. The grade of individual prostate cancer lesions predicted by magnetic resonance imaging and positron emission tomography
3. Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study
4. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
5. Establishing paediatric diagnostic reference levels using reference curves – A feasibility study including conventional and CT examinations
6. Registration of histopathology to magnetic resonance imaging of prostate cancer
7. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
8. Erectile Dysfunction and Absorbed Dose to Penile Base Structures in a Randomized Trial Comparing Ultrahypofractionated and Conventionally Fractionated Radiation Therapy for Prostate Cancer
9. Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial
10. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer
11. 11: Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
12. 2457: Comparison of PET based semi-automatic delineation methods with histopathology as reference
13. 1737: Multiparametric MRI and PET relates to immunoreactivity for prostate specific antigen and Ki67
14. Investigating microRNA Profiles in Prostate Cancer Bone Metastases and Functional Effects of microRNA-23c and microRNA-4328
15. Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events
16. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial
17. Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
18. Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga]PSMA-11-PET and [11C]Acetate-PET.
19. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice
20. Suppl FigS3 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
21. Table S3 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
22. Radiation Therapy Did Not Induce Long-Term Changes in Rectal Mucosa: Results From the Randomized Scandinavian Prostate Cancer Group 7 Trial
23. Additional file 1 of Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study
24. Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
25. IDENTIFICATION OF INTRA-PROSTATIC LESIONS USING PSMA, ACETATE-PET AND MPMRI
26. PROSTATE CANCER RISK CLASSIFICATION FROM MULTIPARAMETRIC MRI AND PET IMAGE DATA EVALUATED BY REGISTERED HISTOPATHOLOGY
27. Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy
28. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone
29. Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study
30. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
31. Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients
32. Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).
33. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
34. Does one have a sexual life 15 years after external beam radiotherapy for prostate cancer? Prospective patient-reported outcome of sexual function comparison with age-matched controls
35. Residual Prostate Cancer in Patients Treated With Endocrine Therapy With or Without Radical Radiotherapy: A Side Study of the SPCG-7 Randomized Trial
36. Secondary Malignancies From Prostate Cancer Radiation Treatment: A Risk Analysis of the Influence of Target Margins and Fractionation Patterns
37. Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C
38. Paediatric diagnostic reference levels for common radiological examinations using the European guidelines
39. Population-based study of long-term functional outcomes after prostate cancer treatment
40. Inhibition of the Insulin-Like Growth Factor-1 Receptor Enhances Effects of Simvastatin on Prostate Cancer Cells in Co-Culture with Bone
41. Validation of the Intestinal Part of the Prostate Cancer Questionnaire “QUFW94”: Psychometric Properties, Responsiveness, and Content Validity
42. PD6-10 ADVERSE EVENTS AFTER RADICAL PROSTATECTOMY AND CURATIVE RADIOTHERAPY. POPULATION-BASED NATION-WIDE REGISTER STUDY
43. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial
44. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
45. Additional file 1 of A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer
46. Additional file 2 of A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer
47. Additional file 5 of A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer
48. Additional file 3 of A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer
49. High Monocyte Count and Expression of S100A9 and S100A12 in Peripheral Blood Mononuclear Cells Are Associated with Poor Outcome in Patients with Metastatic Prostate Cancer
50. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.